These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10335831)

  • 1. US stem-cell pioneers buy 'Dolly' cloning company.
    Wadman M
    Nature; 1999 May; 399(6732):92. PubMed ID: 10335831
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechnology. Stem cells lose market luster.
    Vogel G
    Science; 2003 Mar; 299(5614):1830-1. PubMed ID: 12649456
    [No Abstract]   [Full Text] [Related]  

  • 3. Clones: oddities or businesses?
    Nature; 2002 Aug; 418(6901):903. PubMed ID: 12198503
    [No Abstract]   [Full Text] [Related]  

  • 4. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 5. Stem cells rise in the East.
    Dennis C
    Nature; 2002 Sep; 419(6905):334-6. PubMed ID: 12353004
    [No Abstract]   [Full Text] [Related]  

  • 6. European patents. Tough stance on stem cell, DNA claims.
    Vogel G
    Science; 2002 Aug; 297(5582):754-5. PubMed ID: 12161624
    [No Abstract]   [Full Text] [Related]  

  • 7. Issue of patents on 'Dolly' technology stirs controversy.
    Wadman M
    Nature; 2000 Jan; 403(6768):351-2. PubMed ID: 10667761
    [No Abstract]   [Full Text] [Related]  

  • 8. One of a kind: what did Dolly the sheep really do for us?
    New Sci; 2006 Jul 1-7; 191(2558):5. PubMed ID: 17111515
    [No Abstract]   [Full Text] [Related]  

  • 9. Leaders and laggards in the stem cell enterprise.
    Herrera S
    Nat Biotechnol; 2005 Jul; 23(7):775-7. PubMed ID: 16003350
    [No Abstract]   [Full Text] [Related]  

  • 10. International response to Dolly: will scientific freedom get sheared?
    Cantrell MK
    J Law Health; 1998-1999; 13(1):69-102. PubMed ID: 10788222
    [No Abstract]   [Full Text] [Related]  

  • 11. Deal creates lead cloning company.
    Firn D
    Nat Med; 1999 Jun; 5(6):595. PubMed ID: 10371482
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolly researcher plans further experiments after challenges.
    Butler D
    Nature; 1998 Feb; 391(6670):825-6. PubMed ID: 9495322
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent protection for stem cell procedures under the law of the European Union.
    Spranger TM
    Med Etika Bioet; 2003; 10(1-2):4-8. PubMed ID: 16294439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 17. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnology. Some history should be repeated.
    Feldbaum C
    Science; 2002 Feb; 295(5557):975. PubMed ID: 11834802
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology. Sheep fail to produce golden fleece.
    Vogel G
    Science; 2003 Jun; 300(5628):2015-6. PubMed ID: 12829753
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.